Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 basket study of lenvatinib in relapsed or refractory pediatric and young adult solid tumors
MOH_2020-06-28_008953Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib in glioma, rhabdomyosarcoma (RMS), Ewing sarcoma and 2 more (4 cohorts), sponsored by Merck & Co. Started Mar 2020; status: completed.
02
Drugs
lenvatinib
03
Conditions
gliomarhabdomyosarcoma (RMS)Ewing sarcomaPeripheral Primitive Neuroectodermal Tumor (pPNET)Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2020-06-28_008953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-06-28_008953.